IDEAYA Biosciences IDYA 深 滬
等待開盤 08-10 09:30:00 美东时间
37.02
+0.780
+2.15%
華盛通- 最 高37.03
- 今 開36.50
- 成交量 60.23万股
- 最 低 36.27
- 昨 收 36.24
- 總市值 35.72亿
- 52周最高 40.58
- 市盈率 靜 --
- 換手率 0.62%
- 52周最低 23.23
- 委 比 -10.12%
- 總股本 9648.95万
- 歷史最高 47.735
- 量 比 0.83
- 振 幅 2.10%
- 歷史最低 2.95
- 每 手 1
- 風險率 3.93%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60
Wedbush analyst Robert Driscoll maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $58 to $60.
08-05 21:20
IDEAYA 2026年第二季度财报：注册性试验达标，现金增至12.4亿美元
IDEAYA（IDYA）2026年第二季度合作收入890万美元，净亏损1.125亿美元、每股亏损1.22美元；OptimUM-02达到主要终点，融资后现金及证券增至约12.4亿美元。
08-05 06:20
财报速睇 | IDEAYA Biosciences 2026财年Q2营收0.09亿美元，去年同期为0；归母净利润亏损1.12亿美元，同比亏损扩大45.5%
华盛资讯8月5日讯，IDEAYA Biosciences公布2026财年Q2业绩，公司Q2营收0.09亿美元，去年同期为0，归母净利润亏损1.12亿美元，同比亏损扩大45.5%。
08-05 04:18
财报速睇 | IDEAYA Biosciences 2026财年上半年营收0.15亿美元，去年同期无营收；归母净利润亏损2.11亿美元，同比亏损扩大40.7%
华盛资讯8月4日讯，IDEAYA Biosciences公布2026财年上半年业绩，公司上半年营收0.15亿美元，去年同期无营收，归母净利润亏损2.11亿美元，同比亏损扩大40.7%。
08-04 18:28
IDEAYA Biosciences Q2 EPS $(1.22) Misses $(1.09) Estimate, Sales $8.857M Beat $5.015M Estimate
IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(1.09) by 11.93 percent. This is a 38.64 percent decrease over losses of $(0.88) per share from the same period last year. The company reported quarterly sales of $8.857 mi...
08-04 18:11
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., July 31, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of target...
07-31 18:00
Ideaya Biosciences Initiated Part 2 Monotherapy Expansion In Its Phase 1/2 Trial Of IDE892 In Mtap-Deleted Solid Tumors, With A Focus On Non-small Cell Lung Cancer And Pancreatic Ductal Adenocarcinoma
IDE892 is a potential best-in-class PRMT5 inhibitor with 1,400-fold selective MTA-PRMT5 cooperative binding vs SAM-PRMT5 cooperative binding, and CYP3A4 IC50 greater than 45 micromolar with no time-dependent inhibition of the 7 major cytochrome P450s IDE892 Phase 1/2 escalation has cleared multiple ...
07-27 18:12
IDEAYA Biosciences Announces Presentations At 2026 European Society of Medical Oncology Meeting October 23-27, Providing Updates Across IDEAYA's Clinical Pipeline
IDEAYA Presentations: 2092P (Poster Presentation); Neoadjuvant Darovasertib in Primary Uveal Melanoma: Follow-Up Data from the Phase 2 OptimUM-09 Study. Presenting Author - Mark Shackleton, MBBS, PhD, FRACP, Department of Oncology, Alfred Hospital, and Department of Cancer Medicine, Monash Universit...
07-17 21:04
美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
